Quantcast
Last updated on April 23, 2014 at 15:23 EDT

Latest Clinical trial Stories

2014-04-07 08:31:07

Company Corrects His False Claims About Annual Report and Phase III Trial BETHESDA, Md., April 7, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today again set the record straight: Adam Feuerstein's latest, sensationalized headline claims about the Company's annual report and Phase III trial are once again factually wrong and materially misleading....

2014-04-07 08:29:21

TORONTO, April 7, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) provided an update on the development of its drug candidates and plans for future growth. The addition of the neuropsychiatric drug candidate ELND005 has broadened the Company's development pipeline with an un-partnered late-stage clinical asset, coupled with Transition's core strategy of advancing assets acquired from pharmaceutical partners. From a...

2014-04-04 23:34:34

Innovative Adaptive Designs Increase Trial Flexibility and Efficiency, Generating Significant Ethical and Economic Advantages Reston, Virginia (PRWEB) April 03, 2014 Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the design and implementation of innovative approaches that improve data quality, efficiency, and productivity of product development, will present emerging strategies for using adaptive trial designs to improve the success...

2014-04-04 23:33:41

MPI’s Drug Response Predictor (DRP) can generate new and unique clinically relevant gene signatures - a strong complementary drug development tool; TD2 is an oncology drug development company that customizes clinical trial design and execution for its customers by applying rigorous and high-throughput translational preclinical development, with best in class regulatory and clinical expertise. Scottsdale, Ariz., USA and Hoersholm, Denmark (PRWEB) April 03, 2014 Medical Prognosis...

2014-04-04 08:25:09

REDWOOD CITY, Calif., April 4, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, and Timothy E. Morris, CFO, will present a Company update on April 9(th). Presentation details are as follows: 13(th) Annual Needham Healthcare Conference Date: Wednesday,...

2014-04-03 08:28:44

Company Noted for Quality and On Time Delivery RESEARCH TRIANGLE PARK, N.C., April 3, 2014 /PRNewswire/ -- Marken announced today the completion of an industry wide, independent market research study. The survey included 250 key decision makers of clinical trial logistics services from pharmaceutical companies, central laboratories, clinical research organizations and manufacturing service providers in North America, Central & South America, Europe, and Asia. Key topics profiled...

2014-04-02 23:25:23

The new Clinical Conductor CTMS brings enhanced collaborative and financial functionality that make it the most comprehensive CTMS available. Rochester, NY (PRWEB) April 02, 2014 The new Clinical Conductor CTMS is here, and with it comes a revolution in clinical trial collaboration. The industry’s only true collaborative CTMS takes this capability to a new level. The leading financial capabilities of Clinical Conductor have also been strengthened in this release and provide users...

2014-04-02 20:21:59

Dr. Mark W Jacobson also strengthens clinical team. LAMBERTVILLE, N.J., April 2, 2014 /PRNewswire/ -- CROnos Clinical Consulting, a global neuroscience focused clinical data quality control organization (QCO) with proven processes for delivering results, announced today that Dr. Nina Engelhardt has joined the Company as Vice President, Scientific Innovation. Dr. Engelhardt has been actively involved in innovations in trial methodology and clinical assessment to increase the success...

2014-04-02 08:33:12

Regulatory Clearance Enables Commercialization in Europe and other Key Markets GREENWOOD VILLAGE, Colo., April 2, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc., (NYSE MKT: AMPE) today announced that its subsidiary Luoxis, an in vitro diagnostics company, has obtained CE Marking in Europe for its RedoxSYS(TM) Diagnostic System, the company's blood-based platform for assessing the level of oxidative stress in the body. This regulatory clearance allows Luoxis to engage in strategic...

2014-04-01 23:23:16

Professionals from across East Asia will discuss the latest hot topics in all stages of drug development at the 8th DIA Annual Conference in Japan for Asian New Drug Development. Tokyo, Japan (PRWEB) April 01, 2014 Professionals from across East Asia will discuss the latest hot topics in all stages of drug development at the 8th DIA Annual Conference in Japan for Asian New Drug Development. The event will return for its eighth year on May 22 to 23, at Sola City Hall, Ochanomizu in Tokyo....